Sign in
Taking people in United StatesNo phase

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Key facts

Who runs it
Lauren Moore
Where
Ann Arbor, Atlanta, Baltimore, Boston, Chicago, Dallas, Gainesville, Houston, Los Angeles, Minneapolis, New York, Philadelphia, San Francisco, Seattle, and Tampa, United StatesSee the 16 sitesAlso in 1 other country, 1 site
Trial code
Status
Recruiting
People taking part
1,400 people, planned
Started
Apr 2010
Expected to end
Dec 2030
Type of study
Observational, 3 groups
Treatments tested
  • Genetic Testing
  • Blood Collection
  • Magnetic Resonance Imaging (MRI) Scan
  • Assessments and Questionnaires
  • Cerebrospinal Fluid Collection
Record updated
3 August 2026

Who can take part

Age
6 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Affected individuals aged 6 or above with symptoms and/or signs of ataxia with genetic confirmation of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia either in themselves or first degree family member
  • Any individual aged 18 or above with a definite molecular diagnosis of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia
  • Former participants of the READISCA (NCT03487367) study
  • Willingness to participate in the study and ability to give informed consent
  • For MRI Sub-Study only: Previous READISCA enrollees; individuals aged 18 or above with a genetic confirmation of SCA1, 2, or 3 and a SARA score <10 at MRI pre-screening; Healthy control participants without neurological condition

Who cannot take part

  • Exclusion of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1-ataxia by previous DNA testing
  • For MRI Sub-study only: Inability to undergo MRI scanning, pregnancy, and other neurological diseases than those of interest
  • A lack of willingness to participate in the study

Where in United States

Also in 1 other country, 1 site

  • University of MichiganAnn Arbor, United StatesContact: Frank FerrariTaking people
  • Emory UniversityAtlanta, United StatesContact: Lorena BinghamTaking people
  • John Hopkins UniversityBaltimore, United StatesContact: Vanessa NessporTaking people
  • Harvard UniversityBoston, United StatesContact: Jason MacMoreTaking people
  • Nortwestern UniversityChicago, United StatesContact: Karen WilliamsTaking people
  • University of ChicagoChicago, United StatesContact: Laura P CrespoNo longer taking part
  • University of Texas Southwestern Medical CenterDallas, United StatesContact: Sharon PrimeauxTaking people
  • University of FloridaGainesville, United StatesContact: Amanda FessendenTaking people
  • Houston MethodistHouston, United StatesContact: Noor AlbukhaleefahTaking people
  • University of California, Los AngelesLos Angeles, United StatesContact: Westley UlitTaking people
  • University of MinnesotaMinneapolis, United StatesContact: Laura P CrespoNo longer taking part
  • Columbia UniversityNew York, United StatesContact: Nadia AmokraneTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Anne Beckett-FedarkoTaking people
  • University of California San FranciscoSan Francisco, United StatesContact: Zach LamsonTaking people
  • University of WashingtonSeattle, United StatesContact: Sarah SimonTaking people
  • University of South FloridaTampa, United StatesContact: Lucretia CampbellTaking people

About the trial

What the trial wants to find out

Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCAs and this study will focus on types 1, 2, 3, 6, 7, 8, 10, 27B, and RFC1-ataxia (SCA 1, SCA 2, SCA 3, also known as Machado-Joseph disease, SCA 6, SCA 7, SCA 8, SCA 10, SCA27B, and RFC1-ataxia, also known as CANVAS). The diseases are rare, slowly progressive, cause increasingly severe neurological difficulties, and are variable across and within genotypes. The purpose of this research study is to bring together a group of experts in the field of SCA for the purpose of learning more about the disease.

Read full original descriptionShow less

The research questions are:

1. How do these diseases progress over time? 2. What are the best ways to measure the progression? 3. Do some genes, other than the gene that is abnormal in these diseases, have any effect on the way the disease behaves?

This is a nationwide study and the investigators expect that 1400 patients will participate all over North America. The participants will remain in the study for an indeterminate period of time, for as long as they are willing to participate. Study visits will be done every 12 months.

Within the broader CRC-SCA, there is an Imaging Sub-study aiming to identify magnetic resonance imaging (MRI) markers sensitive to the onset and progression of common SCAs. To accomplish this, participants attend annual visits involving a neurological exam, surveys, a blood draw, and an MRI scan. Participants can attend visits at one of three US locations - Minneapolis, MN; Gainesville, FL; or Dallas, TX and two European locations - Paris, France and Bonn, Germany. Eligible participants must either have SCA1, 2, or 3 or have been a participant of the previous READISCA study (NCT03487367). Gene-positive participants must have a SARA score less than 10; however, there is no SARA limit for participants previously enrolled in READISCA. All participants must be 18 years or older. Gene-negative participants should be 25-65 years old.

The 3 groups in the trial

  • Participants with Spinocerebellar Ataxias (Main Study)

    Individuals aged 6 or older with the spinocerebellar ataxias 1, 2, 3, 6, 7, 8, 10, 27b, or RFC1-Ataxia will be enrolled for genetic testing, blood collection, assessments, and questionnaires.

    Treatment: Genetic Testing, Blood Collection, Assessments and Questionnaires, and Cerebrospinal Fluid Collection

  • Participants with Spinocerebellar Ataxias (MRI Sub-study)

    Adults with the spinocerebellar ataxias 1, 2, and 3 will be enrolled for genetic testing, blood collection, assessments, questionnaires, and magnetic resonance imaging (MRI).

    Treatment: Genetic Testing, Blood Collection, Magnetic Resonance Imaging (MRI) Scan, and Assessments and Questionnaires

  • Healthy Controls (MRI Sub-study)

    Adults without spinocerebellar ataxias or other neurological conditions will be enrolled for genetic testing, blood collection, assessments, questionnaires, and magnetic resonance imaging (MRI).

    Treatment: Genetic Testing, Blood Collection, Magnetic Resonance Imaging (MRI) Scan, and Assessments and Questionnaires

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Research Consortium for the Study of Cerebellar Ataxias (CRC-SCA) for the Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias (SCA)
Record updated
3 August 2026